Vol[removed]No. 24 MMWR 605

First Page		Document Content
Date: 2010-03-18 11:33:27 Mycobacterium bovis M. bovis Mycobacterium Pyrazinamide HIV Tuberculosis treatment Bacteria Tuberculosis Microbiology		Vol[removed]No. 24 MMWR 605 Add to Reading List Source URL: biotech.law.lsu.edu Download Document from Source Website File Size: 100,53 KB Share Document on Facebook

	For immediate release March 21, 2017 Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis Moscow, Russia and Rockville, MD, USA -- Infecte DocID: 1vkmw - View Document
	PRESS RELEASE Adequate treatment essential to stop TB across Europe – new ECDC/WHO report Stockholm/Copenhagen, 19 MarchOverpatients are estimated to fall sick with tuberculosis (TB) every day across Euro DocID: 1saSR - View Document
	JOINT PRESS RELEASE New ECDC-WHO report: tuberculosis on the retreat in Europe. Concerns about drugresistant TB and treatment failure. Stockholm/Copenhagen, 19 March 2012 DocID: 1rHnT - View Document
	15 \| P a g e Multiple healthcare Seeking behaviors of new Smear positive pulmonary tuberculosis patients attending a diagnosis and treatment center of Bafoussam- Cameroon ABSTRACT FABRICE NEMBOT DJOUMA , ARMELLE VIVIAN DocID: 1qzgC - View Document
	Embargoed: 12 May – 1130 hrs CEST WORLD HEALTH ORGANIZATION RECOMMENDS SHORTENED NINE-MONTH TREATMENT REGIMEN FOR MDR-TB PATIENTS DocID: 1q2l5 - View Document